NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Rostom A, Dube C, Lewin G. Use of Aspirin and NSAIDs to Prevent Colorectal Cancer [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Mar. (Evidence Syntheses, No. 45.)

Cover of Use of Aspirin and NSAIDs to Prevent Colorectal Cancer

Use of Aspirin and NSAIDs to Prevent Colorectal Cancer [Internet].

Show details

Appendix 8. Figures and Tables

References for Appendix 8

1.
Bigler J, Whitton J, Lampe JW. et al. CYP2C9 and UGT1A6 genotypes modulate the protective effect of aspirin on colon adenoma risk. Cancer Res. 2001;61(9):3566–3569. [PubMed: 11325819]
2.
Martinez ME, McPherson RS, Levin B. et al. Aspirin and other nonsteroidal anti-inflammatory drugs and risk of colorectal adenomatous polyps among endoscoped individuals. Cancer Epidemiol Biomarkers Prev. 1995;4(7):703–707. [PubMed: 8672985]
3.
Logan RF, Little J, Hawtin PG. et al. Effect of aspirin and non-steroidal anti-inflammatory drugs on colorectal adenomas: case-control study of subjects participating in the Nottingham faecal occult blood screening programme. BMJ. 1993;307(6899):285–289. [PMC free article: PMC1678595] [PubMed: 8374373]
4.
Suh O, Mettlin C, Petrelli NJ. Aspirin use, cancer, and polyps of the large bowel. Cancer. 1993;72(4):1171–1177. [PubMed: 8339210]
5.
Hauret KG, Bostick RM, Matthews CE. et al. Physical activity and reduced risk of incident sporadic colorectal adenomas: observational support for mechanisms involving energy balance and inflammation modulation. Am J Epidemiol. 2004;159(10):983–992. [PubMed: 15128611]
6.
Lieberman DA, Prindiville S, Weiss DG. et al. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA. 2003;290(22):2959–2967. [PubMed: 14665657]
7.
Martin C, Connelly A, Keku TO. et al. Nonsteroidal anti-inflammatory drugs, apoptosis, and colorectal adenomas. Gastroenterology. 2002;123(6):1770–1777. [PubMed: 12454832]
8.
Garcia Rodriguez LA, Huerta-Alvarez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal antiinflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology. 2000;11(4):376–381. [PubMed: 10874542]
9.
Breuer-Katschinski B, Nemes K, Rump B. et al. Long-term use of nonsteroidal antiinflammatory drugs and the risk of colorectal adenomas. The Colorectal Adenoma Study Group. Digestion. 2000;61(2):129–134. [PubMed: 10705177]
10.
Kahn HS, Tatham LM, Thun MJ. et al. Risk factors for self-reported colon polyps. J Gen Intern Med. 1998;13(5):303–310. [PMC free article: PMC1496952] [PubMed: 9613885]
11.
Sandler RS, Galanko JC, Murray SC. et al. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology. 1998;114(3):441–447. [PubMed: 9496933]
12.
Peleg II, Lubin MF, Cotsonis GA. et al. Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia. Dig Dis. 1996;41(7):1319–1326. [PubMed: 8689906]
13.
Boyapati SM, Bostick RM, McGlynn KA. et al. Calcium, vitamin D, and risk for colorectal adenoma: dependency on vitamin D receptor BsmI polymorphism and nonsteroidal anti-inflammatory drug use? Cancer Epidemiol Biomarkers Prev. 2003;12(7):631–637. [PubMed: 12869402]
14.
Chan AT, Giovannucci EL, Schernhammer ES. et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med. 2004;140(3):157–166. [PubMed: 14757613]
15.
Giovannucci E, Rimm EB, Stampfer MJ. et al. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med. 1994;121(4):241–246. [PubMed: 8037405]
16.
Greenberg ER, Baron JA, Freeman DH Jr. et al. Reduced risk of large-bowel adenomas among aspirin users. The Polyp Prevention Study Group. J Natl Cancer Inst. 1993;85(11):912–916. [PubMed: 8492320]
17.
Tangrea JA, Albert PS, Lanza E. et al. Non-steroidal anti-inflammatory drug use is associated with reduction in recurrence of advanced and non-advanced colorectal adenomas (United States) Cancer Causes Control. 2003;14(5):403–411. [PubMed: 12946034]
18.
Baron JA, Cole BF, Sandler RS. et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med. 2003;348(10):891–899. [PubMed: 12621133]
19.
Benamouzig R, Deyra J, Martin A. et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology. 2003;125(2):328–336. [PubMed: 12891533]
20.
Gann PH, Manson JE, Glynn RJ. et al. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J Natl Cancer Inst. 1993;85(15):1220–1224. [PubMed: 8331682]
21.
Ladenheim J, Garcia G, Titzer D. et al. Effect of sulindac on sporadic colonic polyps. Gastroenterology. 1995;108(4):1083–1087. [PubMed: 7698575]
22.
Garcia Rodriguez LA, Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiology. 2001;12(1):88–93. [PubMed: 11138826]
23.
La Vecchia C, Negri E, Franceschi S. et al. Aspirin and colorectal cancer. Br J Cancer. 1997;76(5):675–677. [PMC free article: PMC2228005] [PubMed: 9303370]
24.
Muscat JE, Stellman SD, Wynder EL. Nonsteroidal antiinflammatory drugs and colorectal cancer. Cancer. 1994;74(7):1847–1854. [PubMed: 8082089]
25.
Kune GA, Kune S, Watson LF. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res. 1988;48(15):4399–4404. [PubMed: 3390835]
26.
Shaheen NJ, Silverman LM, Keku T. et al. Association between hemochromatosis (HFE) gene mutation carrier status and the risk of colon cancer. J Natl Cancer Inst. 2003;95(2):154–159. [PubMed: 12529348]
27.
Juarranz M, Calle-Puron ME, Gonzalez-Navarro A. et al. Physical exercise, use of Plantago ovata and aspirin, and reduced risk of colon cancer. Eur J Cancer Prev. 2002;11(5):465–472. [PubMed: 12394244]
28.
Coogan PF, Rosenberg L, Louik C. et al. NSAIDs and risk of colorectal cancer according to presence or absence of family history of the disease. Cancer Causes Control. 2000;11(3):249–255. [PubMed: 10782659]
29.
Collet JP, Sharpe C, Belzile E. et al. Colorectal cancer prevention by non-steroidal anti-inflammatory drugs: effects of dosage and timing. Br J Cancer. 1999;81(1):62–68. [PMC free article: PMC2374346] [PubMed: 10487613]
30.
Reeves MJ, Newcomb PA, Trentham-Dietz A. et al. Nonsteroidal anti-inflammatory drug use and protection against colorectal cancer in women. Cancer Epidemiol Biomarkers Prev. 1996;5(12):955–960. [PubMed: 8959316]
31.
Slattery ML, Samowitz W, Hoffman M. et al. Aspirin, NSAIDs, and colorectal cancer: Possible involvement in an insulin-related pathway. Cancer Epidemiol Biomarkers Prev. 2004;13(4):538–545. [PubMed: 15066917]
32.
Sturmer T, Glynn RJ, Lee IM. et al. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann Intern Med. 1998;128(9):713–720. [PubMed: 9556464]
33.
Giovannucci E, Egan KM, Hunter DJ. et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med. 1995;333(10):609–614. [PubMed: 7637720]
34.
Schreinemachers DM, Everson RB. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. epi. 1994;5(2):138–146. [PubMed: 8172988]
35.
Thun MJ, Namboodiri MM, Heath CW Jr. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med. 1991;325(23):1593–1596. [PubMed: 1669840]
36.
Lipworth L, Friis S, Blot WJ. et al. A population-based cohort study of mortality among users of ibuprofen in Denmark. Am J Ther. 2004;11(3):156–163. [PubMed: 15133529]
37.
Sorensen HT, Friis S, Norgard B. et al. Risk of cancer in a large cohort of nonaspirin NSAID users: a population-based study. Br J Cancer. 2003;88(11):1687–1692. [PMC free article: PMC2377131] [PubMed: 12771981]
38.
Friis S, Sorensen HT, McLaughlin JK. et al. A population-based cohort study of the risk of colorectal and other cancers among users of low-dose aspirin. Br J Cancer. 2003;88(5):684–688. [PMC free article: PMC2376336] [PubMed: 12618874]
39.
Smalley W, Ray WA, Daugherty J. et al. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer: a population-based study. Arch Intern Med. 1999;159(2):161–166. [PubMed: 9927099]
40.
Paganini-Hill A. Aspirin and colorectal cancer: the Leisure World cohort revisited. Prev Med. 1995;24(2):113–115. [PubMed: 7597009]
41.
Rosenberg L, Louik C, Shapiro S. Nonsteroidal antiinflammatory drug use and reduced risk of large bowel carcinoma. Cancer. 1998;82(12):2326–2333. [PubMed: 9635524]
42.
Rosenberg L, Palmer JR, Zauber AG. et al. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J Natl Cancer Inst. 1991;83(5):355–358. [PubMed: 1759994]
43.
Friedman GD, Coates AO, Potter JD. et al. Drugs and colon cancer. Pharmacoepidemiol Drug Saf. 1998;7(2):99–106. [PubMed: 15073733]
44.
Morimoto LM, Newcomb PA, Ulrich CM. et al. Risk factors for hyperplastic and adenomatous polyps: evidence for malignant potential? Cancer Epidemiol Biomarkers Prev. 2002;11(10 Pt 1):1012–1018. [PubMed: 12376501]
45.
Gibbs WJ, Fugate SE, Vesta KS. Optimal antithrombotic management of anticoagulated patients with a history of myocardial infarction. [Review] [16 refs] Cardiol Rev. 2004;12(6):327–333. [PubMed: 15476572]
46.
Hart RG, Halperin JL, McBride R. et al. Aspirin for the primary prevention of stroke and other major vascular events: meta-analysis and hypotheses. Arch Neurol. 2000;57(3):326–332. [PubMed: 10714657]
47.
Hayden M, Pignone M, Phillips C. et al. Aspirin for the primary prevention of cardiovascular events: a summary of the evidence for the U.S. Preventive Services Task Force. Ann Intern Med. 2002;136(2):161–172. [PubMed: 11790072]
48.
He J, Whelton PK, Vu B. et al. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA. 1998;280(22):1930–1935. [PubMed: 9851479]
49.
Weisman SM, Graham DY. Evaluation of the benefits and risks of low-dose aspirin in the secondary prevention of cardiovascular and cerebrovascular events. Arch Intern Med. 2002;162(19):2197–2202. [PubMed: 12390062]
50.
Serebruany VL, Malinin AI, Eisert RM. et al. Risk of bleeding complications with antiplatelet agents: meta-analysis of 338,191 patients enrolled in 50 randomized controlled trials. Am J Hematol. 2004;75(1):40–47. [PubMed: 14695631]
51.
Lip GY, Felmeden DC. Antiplatelet agents and anticoagulants for hypertension. [Review][117 refs]. Cochrane Database Syst Rev 2004;(3):CD003186. [PubMed: 15266473]
52.
Derry S, Loke YK. Risk of gastrointestinal haemorrhage with long term use of aspirin: meta-analysis. BMJ. 2000;321(7270):1183–1187. [PMC free article: PMC27521] [PubMed: 11073508]
53.
Garcia Rodriguez LA, Hernandez-Diaz S, de Abajo FJ. Association between aspirin and upper gastrointestinal complications: systematic review of epidemiologic studies. Br J Clin Pharmacol. 2001;52(5):563–571. [PMC free article: PMC2014603] [PubMed: 11736865]
54.
Tramer MR, Moore RA, Reynolds DJ. et al. Quantitative estimation of rare adverse events which follow a biological progression: a new model applied to chronic NSAID use. Pain. 2000;85(12):169–182. [PubMed: 10692616]
55.
Roderick PJ, Wilkes HC, Meade TW. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br J Clin Pharmacol. 1993;35(3):219–226. [PMC free article: PMC1381566] [PubMed: 8471398]
56.
Huang JQ, Sridhar S, Hunt RH. Role of Helicobacter pylori infection and non-steroidal anti-inflammatory drugs in peptic-ulcer disease: a meta-analysis. Lancet. 2002;359(9300):14–22. [PubMed: 11809181]
57.
Ofman JJ, MacLean CH, Straus WL. et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 2002;29(4):804–812. [PubMed: 11950025]
58.
Ofman JJ, MacLean CH, Straus WL. et al. Meta-analysis of dyspepsia and nonsteroidal antiinflammatory drugs. Arthritis Rheum. 2003;49(4):508–518. [PubMed: 12910557]
59.
Rostom, A., Dube, C., Jolicoeur, E., Boucher, M., and Joyce, J. Gastroduodenal ulcers associated with the use of non-steroidal anti-inflammatory drugs: a systematic review of preventative pharmacological interventions. Ottawa: CCOHTA, 2004. Technology Report Issue 38.
60.
Hooper L, Brown TJ, Elliott R. et al. The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review. BMJ. 2004;329(7472):948. [PMC free article: PMC524106] [PubMed: 15475342]
61.
Garner S, Fidan D, Frankish R et al. Celecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2002;(4):CD003831. [PubMed: 12519610]
62.
Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325(7365):619. [PMC free article: PMC126301] [PubMed: 12242171]
63.
Edwards JE, McQuay HJ, Moore RA. Efficacy and safety of valdecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. [Review] [31 refs] Pain. 2004;111(3):286–296. [PubMed: 15363872]
64.
Garner SE, Fidan DD, Frankish R et al. Rofecoxib for osteoarthritis. Cochrane Database Syst Rev 2005;(1):CD005115. [PubMed: 15654705]
65.
Garner SE, Fidan DD, Frankish RR et al. Rofecoxib for rheumatoid arthritis. Cochrane Database Syst Rev 2005;(1):CD003685. [PubMed: 15674912]
66.
Gomez CJ, Lubomirov HR, Carcas Sansuan AJ. et al. Outcome trials of COX-2 selective inhibitors: global safety evaluation does not promise benefits. Eur J Clin Pharmacol. 2003;59(2):169–175. [PubMed: 12698301]
67.
Mukherjee D, Nissen SE, Topol EJ. Risk of cardiovascular events associated with selective COX-2 inhibitors. JAMA. 2001;286(8):954–959. [PubMed: 11509060]
68.
Juni P, Nartey L, Reichenbach S. et al. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis. Lancet. 2004;364(9450):2021–2029. [PubMed: 15582059]
69.
Ashcroft DM, Chapman SR, Clark WK. et al. Upper gastroduodenal ulceration in arthritis patients treated with celecoxib. Ann Pharmacother. 2001;35(78):829–834. [PubMed: 11485128]
70.
Goldstein JL, Eisen GM, Agrawal N. et al. Reduced incidence of upper gastrointestinal ulcer complications with the COX-2 selective inhibitor, valdecoxib. Aliment Pharmacol Ther. 2004;20(5):527–538. [PubMed: 15339324]
71.
Schoenfeld P. Gastrointestinal safety profile of meloxicam: a meta-analysis and systematic review of randomized controlled trials. Am J Med. 1999;107(6A):48S–54S. [PubMed: 10628593]
72.
Eisen GM, Goldstein JL, Hanna DB. et al. Meta-analysis: upper gastrointestinal tolerability of valdecoxib, a cyclooxygenase-2-specific inhibitor, compared with nonspecific nonsteroidal anti-inflammatory drugs among patients with osteoarthritis and rheumatoid arthritis. Aliment Pharmacol Ther. 2005;21(5):591–598. [PubMed: 15740543]
73.
Suleiman S, Rex DK, Sonnenberg A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastroenterology. 2002;122(1):78–84. [PubMed: 11781283]
74.
Ladabaum U, Chopra CL, Huang G. et al. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann Intern Med. 2001;135(9):769–781. [PubMed: 11694102]
75.
Ladabaum U, Scheiman JM, Fendrick AM. Potential effect of cyclooxygenase-2 - Specific inhibitors on the prevention of colorectal cancer: A cost-effectiveness analysis. Am J Med. 2003;114(7):546–554. [PubMed: 12753878]
76.
Arguedas MR, Heudebert GR, Wilcox CM. Surveillance colonoscopy or chemoprevention with COX-2 inhibitors in average-risk post-polypectomy patients: a decision analysis. Aliment Pharmacol Ther. 2001;15(5):631–638. [PubMed: 11328256]
77.
Hur C, Simon LS, Gazelle GS. The cost-effectiveness of aspirin versus cyclooxygenase-2-selective inhibitors for colorectal carcinoma chemoprevention in healthy individuals. Cancer. 2004;101(1):189–197. [PubMed: 15222006]
PubReader format: click here to try

Views

  • PubReader
  • Print View
  • Cite this Page

Related information

  • PMC
    PubMed Central citations
  • PubMed
    Links to pubmed

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...